Aims: The effects of the novel water soluble, viscous fiber complex PolyGlycopleX® [(α-D-glucurono-α-D-manno-β-D-manno-β-D-gluco), (α-L-gulurono-β-D mannurono), β-D-gluco-β-D-mannan (PGX®)] on body weight, food consumption, glucose, insulin, and glucagon-like peptide (GLP-1) levels were determined in Zucker diabetic rats (ZDFs). Such fibers are thought to improve glycemic control through increased GLP-1 induced insulin secretion.
Main Methods: ZDFs were treated 12 weeks with normal rodent chow supplemented with cellulose (control, inert fiber), inulin or PGX® at 5% wt/wt and effects on body weight, glycemic control, and GLP-1 determined.
Key Findings: In the fed state, PGX® reduced blood glucose compared to the other groups from week 5 until study termination while insulin was significantly elevated when measured at week 9, suggesting an insulin secretagogue effect. Fasting blood glucose was similar among groups until 7-8 weeks when levels began to climb with a modest reduction caused by PGX®. An oral glucose tolerance test in fasted animals (week 11) showed no change in insulin sensitivity scores among diets, suggesting an insulinotropic effect for PGX® rather than increased insulin sensitivity. PGX® increased plasma levels of GLP-1, while HbA(1c) was markedly reduced by PGX®. Body weights were not changed despite a significant reduction in food consumption induced by PGX® up to week 8 when the PGX®-treated group showed an increase in body weight despite a continued reduction in food consumption.
Significance: PGX® improved glycemic control and reduced protein glycation, most likely due to the insulin secretagogue effects of increased GLP-1.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.lfs.2010.11.014 | DOI Listing |
Open Med (Wars)
January 2025
Endocrine Department, 920th Hospital of Joint Logistics Support Force, PLA, No. 212 Daguan Road, Xishan District, Kunming, 650000, Yunnan, China.
Background: Diabetes-related cognitive impairment is increasingly recognized as a significant complication, profoundly impacting patients' quality of life. This review aims to examine the pathophysiological mechanisms, clinical manifestations, risk factors, assessment and diagnosis, management strategies, and future research directions of cognitive impairment in diabetes.
Methodology: A comprehensive literature search was conducted using PubMed, Medline, and other medical databases to identify, review, and evaluate published articles on cognitive impairment in diabetes.
Am J Transl Res
December 2024
Department of Anesthesiology, Perioperative and Pain Medicine, Nanjing First Hospital, Nanjing Medical University Nanjing, Jiangsu, China.
Objectives: To retrospectively investigate the effect of a mobile app-based self-care diary, a nursing management method, on post-heart transplantation diabetes.
Methods: A retrospective analysis was conducted on the general data of 87 patients who underwent heart transplantation in the Cardiac and Thoracic Vascular Surgery Department of Nanjing First Hospital between January 2018 and December 2023. Based on the nursing method, the patients were divided into a control group that received routine nursing measures (n=47 cases) and an observation group that implemented a mobile APP-based self-care diary combined with nursing (n=40 cases).
J Clin Endocrinol Metab
January 2025
College of Nursing, Department of Biobehavioral Nursing Science, University of Illinois Chicago, Chicago, Illinois.
Context: Sleep health is multidimensional. While studies have shown associations between certain sleep dimensions and health in type 1 diabetes (T1D), global sleep health has rarely been considered.
Objective: To examine the associations between individual sleep dimensions and multidimensional sleep health (MSH) on glycemic control and self-reported outcomes in T1D.
Curr Vasc Pharmacol
January 2025
1st Department of Cardiology, 'Hippokration' General Hospital, National and Kapodistrian University of Athens, 11527 Athens, Greece.
Introduction: Sodium-glucose cotransporter 2 (SGLT2) inhibitors have emerged as a groundbreaking class of antidiabetic medications renowned for their glucose-lowering effects and cardiovascular benefits. Recent studies have suggested that SGLT2 inhibitors may extend their influence beyond glycemic control to impact adipose tissue physiology, particularly within the epicardial adipose depot. Epicardial adipose tissue (EAT), an actively secretory organ surrounding the heart, has been implicated in the modulation of cardiovascular risk.
View Article and Find Full Text PDFJ Diabetes Sci Technol
January 2025
Clinical and Biomedical Sciences, University of Exeter, Exeter, UK.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!